网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
乳腺浸润性导管癌中PDGF-BB表达与预后的关系
作者:李龙均  付明刚 
单位:新疆医科大学第一附属医院 乳腺外科, 新疆 乌鲁木齐 830011
关键词:乳腺浸润性导管癌 血小板源性生长因子-BB 免疫组织化学 预后 
分类号:R737.9
出版年·卷·期(页码):2020·48·第九期(1101-1106)
摘要:

目的:探讨血小板源性生长因子-BB(PDGF-BB)表达与乳腺浸润性导管癌临床预后的关系。方法:采用免疫组化法检测115例乳腺浸润性导管癌组织PDGF-BB表达,应用卡方检验分析PDGF-BB表达与临床病理特征的关系,Kaplan-Meier法计算中位无瘤生存时间,Log-rank检验比较不同PDGF-BB表达中位无瘤生存时间的差异,采用Cox回归模型进行多因素生存分析。结果:PDGF-BB阳性表达与有无淋巴结转移、肿瘤直径有关(P<0.05);在不同年龄、月经状态、孕激素受体(PR)、雌激素受体(ER)、人类表皮生长因子受体-2(HER-2)状态等临床病理特征上PDGF-BB阳性表达率的差异无统计学意义(P>0.05)。PDGF-BB阳性表达者的中位无瘤生存时间较PDGF-BB阴性表达者短,差异有统计学意义(P<0.05);PDGF-BB阳性表达(HR=3.821,95% CI:1.139~2.810,P=0.030)、发生淋巴结转移(HR=2.708,95% CI:1.129~6.494,P=0.026)、HER-2阳性(HR=3.651,95% CI:1.667~7.999,P=0.001)是乳腺浸润性导管癌预后的独立危险因素,PR阳性(HR=0.437,95% CI:0.209~0.913,P=0.028)、接受化疗(HR=0.150,95% CI:0.040~0.559,P=0.005)是乳腺浸润性导管癌预后的独立保护因素。结论:PDGF-BB表达促进乳腺癌浸润性导管癌进展,是影响预后的独立因素,可以作为乳腺浸润性导管癌预后评估的临床指标。

Objective: To explore the relationship between the expression ofplatelet-derived growth factor-BB (PDGF-BB)in breast invasive ductal carcinoma and clinical prognosis.Methods: Immunohistochemistry was used to detect the expression of PDGF-BB in 115 cases of breast invasive ductal carcinoma. Chi-square test was employed to analyze the relationship between the expression of PDGF-BB and the clinicopathological characteristics. Kaplan Meier method was used to calculate the median tumor free survival time. Log-rank test was used to compare the difference between the median tumor free survival time and different PDGF-BB expressions. Cox regression model was used to analyze the multifactor survival.Results: The positive expression of PDGF-BB was related to the lymph node metastasis and tumor diameter(P<0.05).There was no significant difference in PDGF-BB positive expression rate in different ages, menstrual status, progesterone receptor(PR), estrogen receptor(ER), human epidemal growth factor receptor-2(HER-2) status(P>0.05). The median tumor free survival time of PDGF-BB positive expression was shorter than that of PDGF-BB negative expression (P<0.05). PDGF-BB positive expression(HR=3.821,95% CI:1.139~2.810,P=0.030), lymph node metastasis(HR=2.708,95% CI:1.129-6.494,P=0.026). HER-2 positive (HR=3.651,95% CI:1.667~7.999,P=0.001)were independent risk factors for prognosis of breast invasive ductal carcinoma, and PR positive(HR=0.437,95% CI:0.209~0.913,P=0.028) and chemotherapy(HR=0.150, 95% CI:0.040~0.559, P=0.005)were independent protective factors for prognosis of breast invasive ductal carcinoma. Conclusion: The expression of PDGF-BB can promote the progression of invasive ductal carcinoma of breast, which is an independent factor affecting the prognosis, and can be used as a clinical indicator for the prognosis evaluation of invasive ductal carcinoma of breast.

参考文献:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] HUANG Z,WEN W,ZHENG Y,et al.Breast cancer incidence and mortality:trends over 40 years among women in Shanghai,China[J].Ann Oncol,2016,27(6):1129-1134.
[3] GIALELI C,NIKITOVIC D,KLETSA S D,et al.PDGF/PDGFR signaling and targeting in cancer growth and progression:focus on tumor microenvironment and cancer-associated fibroblasts[J].Curr Pharm Des,2014,20(17):2843-2848.
[4] ROBERTA M,LOREDANA B,CLAUDIA G,et al.The role of PDGFs and PDGFRs in colorectal cancer[J].Mediators Inflamm,2017(1):4708076-4708085.
[5] CIMPEAN A M,COBEC I M,CEAUSURA R A,et al.Platelet derived growth factor BB:a "must-have" therapeutic target "redivivus" in ovarian cancer[J].Cancer Genomics Proteomics,2016,13(6):511-517.
[6] CHEN B,LIU J H,WANG X H,et al.Co-expression of PDGF-B and VEGFR-3 strongly correlates with poor prognosis in hepatocellular carcinoma patients after hepatectomy[J].Clin Res Hepatol Gastroenterol,2018,42(2):126-133.
[7] KARAVASILIS V,MALAMOU-MITSI V,BRIASOULIS E,et al.Angiogenesis in cancer of unknown primary:clinicopathological study of CD34,VEGF and TSP-1[J].BMC Cancer,2005,5(3):25.
[8] ESBAH O,OKSUZOGLU B.Prognostic and predictive factors for planning adjuvant chemotherapy of early-stage breast cancer[J].Indian J Med Res,2017,146(5):563-571.
[9] 靳继海,刘玉娟,王强.妊娠相关乳腺癌的临床和病理特点及预后的影响因素分析[J].东南大学学报(医学版),2018,37(3):440-444.
[10] KOSTOPOULOS S A,VASSIOU K G,LAVDAS E N,et al.Computer-based automated estimation of breast vascularity and correlation with breast cancer in DCE-MRI images[J].Magn Reson Imaging,2017,35(1):39-45.
[11] ROSKOSKI R J R.The role of small molecule platelet-derived growth factor receptor(PDGFR) inhibitors in the treatment of neoplastic disorders[J].Pharmacol Res,2018,129(3):65-83.
[12] KAZLAUSKAS A.PDGFs and their receptors[J].Gene,2017,614(5):1-7.
[13] HSU Y L,YEN M C,CHANG W A,et al.CXCL17-derived CD11b+Gr-1+myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB[J].Breast Cancer Res,2019,21(1):23-23.
[14] JABEEN S,ESPINOZA J A,TORLAND L A,et al.Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics[J].Oncoimmunology,2018,8(2):1537691-1537691.
[15] 亓军,张远鹏,任维才,等.PDGF-BB、VEGF-D与结肠癌发生及淋巴转移的关系[J].中国现代普通外科进展,2018,21(12):998-1000.
[16] DING M,HE S J,YANG J.MCP-1/CCL2 mediated by autocrine loop of PDGF-BB promotes invasion of lung cancer cell by recruitment of macrophages via CCL2-CCR2 Axis[J].J Interferon Cytokine Res,2019,39(4):224-232.
[17] LIU J,LIU C,QIU L,et al.Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymph angiogenesis in primary human non-small cell lung cancer[J].Diagn Pathol,2014,9(6):128.
[18] CAO R,BJOMDAHL M A,RELIGA P,et al.PPDGF-BB induces intratumoral lymph angiogenesis and promotes lymphatic metastasis[J].Cancer Cell,2006,9(3):239.
[19] NERI S,MIYASHITA T,HASHIMOTO H,et al.Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma[J].Cancer Lett,2017,395(1):20-30.
[20] SAE-LIM S,SOONTORNWORAJIT B,ROTKRUA P.Inhibition of colorectal cancer cellproliferation by regulating platelet-derived growth factor B signaling with a DNA aptamer[J].Asian Pac J Cancer Prev,2019,20(2):487-494.
[21] JUNG S H,LEE GB,RYU Y,et al.Inhibitory effects of scoparone from chestnut inner shell on platelet-derived growth factor-BB-induced vascular smooth muscle cell migration and vascular neointima hyperplasia[J].J Sci Food Agric,2019,99(9):4397-4406.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 399318 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541